STAT3 is an oncogenic transcription factor that is hyperactivated in many cancers, contributing to growth, survival and therapeutic resistance. The mechanisms mediating increased STAT3 activation in human cancers are incompletely understood. Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer mortality worldwide. We previously reported increased STAT3 activation in HNSCC associated with treatment resistance. Previous reports indicate that protein tyrosine receptor phosphatases T (PTPRT) and D (PTPRD) negatively regulate STAT3 activation. We determined the mutational profile of HNSCC, and detected mutations in the PTPR family in nearly one-third of the cases analyzed. Studies proposed here will test the hypothesis that aberrant STAT3 activation results from PTPR mutations, and that STAT3 is a key therapeutic target in cancers harboring these mutations. We have developed a STAT3-selective decoy that inhibits STAT3 target gene expression in HNSCC tumors treated on a recently completed phase 0 trial. In addition, preliminary evidence indicates that the JAK/STAT inhibitor AZD1480 abrogates STAT3 activation and HNSCC growth. We propose to determine whether tumors that harbor PTPR mutations demonstrate enhanced sensitivity to STAT3 inhibition using relevant preclinical HNSCC models and our unique access to tumors from HNSCC patients enrolled in a presurgical trial of a small molecule JAK/STAT inhibitor.
Signal Transducer and Activator of Transcription 3 (STAT3) is an oncogenic transcription factor that is hyperactivated in a wide variety of cancers, where STAT3 contributes to growth, survival and therapeutic resistance. The mechanisms contributing to increased STAT3 activation in human cancers are incompletely understood. Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer mortality worldwide. We previously reported that STAT3 activation is increased in HNSCC and confers resistance to treatment. Previous studies suggest that protein tyrosine receptor phosphatases T (PTPRT) and D (PTPRD) negatively regulate STAT3 activation. We recently reported the mutational profile of HNSCC, and detected mutations in the PTPR family (including PTPRT, PTPRD) in nearly one third of the cases analyzed. The proposed studies will: 1) determine the contribution of PTPR mutations to STAT3 activation and tumor growth in HNSCC preclinical models;2) elucidate the biological impact of STAT3 inhibitors in HNSCC models harboring PTPR mutations;and 3) determine the in vivo antitumor efficacy of STAT3 inhibition in heterotopic HNSCC tumorgrafts and specimens from HNSCC patients treated on a window-of-opportunity trial with a JAK/STAT inhibitor. Overall, our objective is to identify the subset of HNSCC patients where treatment with a STAT3 targeting agent represents a particularly effective therapeutic strategy.
|Johnson, Daniel E; O'Keefe, Rachel A; Grandis, Jennifer R (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234-248|
|Sen, Malabika; Johnston, Paul A; Pollock, Netanya I et al. (2017) Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol 10:129-141|
|Geiger, Jessica L; Grandis, Jennifer R; Bauman, Julie E (2016) The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol 56:84-92|
|Bhola, Neil E; Johnson, Daniel E; Grandis, Jennifer R (2016) A sensible approach to targeting STAT3-mediated transcription. Ann Transl Med 4:S57|
|Peyser, N D; Freilino, M; Wang, L et al. (2016) Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 35:1163-9|
|Peyser, Noah D; Pendleton, Kelsey; Gooding, William E et al. (2016) Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS One 11:e0166185|
|Peyser, Noah D; Wang, Lin; Zeng, Yan et al. (2016) STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila) 9:657-63|
|Du, Yu; Grandis, Jennifer R (2015) Receptor-type protein tyrosine phosphatases in cancer. Chin J Cancer 34:61-9|
|Wheeler, Sarah E; Egloff, Ann Marie; Wang, Lin et al. (2015) Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One 10:e0117781|
|Peyser, Noah D; Du, Yu; Li, Hua et al. (2015) Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS One 10:e0135750|
Showing the most recent 10 out of 67 publications